RU2015109591A - Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами - Google Patents
Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами Download PDFInfo
- Publication number
- RU2015109591A RU2015109591A RU2015109591A RU2015109591A RU2015109591A RU 2015109591 A RU2015109591 A RU 2015109591A RU 2015109591 A RU2015109591 A RU 2015109591A RU 2015109591 A RU2015109591 A RU 2015109591A RU 2015109591 A RU2015109591 A RU 2015109591A
- Authority
- RU
- Russia
- Prior art keywords
- sufferer
- domain
- domains
- multimerizing
- igg2
- Prior art date
Links
- 230000027455 binding Effects 0.000 title 2
- 102000009490 IgG Receptors Human genes 0.000 title 1
- 108010073807 IgG Receptors Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 12
- 229960000310 isoleucine Drugs 0.000 claims abstract 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 7
- 150000001413 amino acids Chemical group 0.000 claims abstract 6
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical group CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691057P | 2012-08-20 | 2012-08-20 | |
| US61/691,057 | 2012-08-20 | ||
| US201361785144P | 2013-03-14 | 2013-03-14 | |
| US61/785,144 | 2013-03-14 | ||
| PCT/US2013/055800 WO2014031646A2 (en) | 2012-08-20 | 2013-08-20 | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015109591A true RU2015109591A (ru) | 2016-10-20 |
Family
ID=50150476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015109591A RU2015109591A (ru) | 2012-08-20 | 2013-08-20 | Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9683044B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2885320A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015527366A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150058236A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104718223A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013305885B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015003459A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2882296A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1210792A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL237307A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015002269A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015109591A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014031646A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394440B (es) | 2007-06-01 | 2025-03-24 | Univ Maryland | Agentes de union al receptor de la region constante fc de inmunoglobulina. |
| TR201906652T4 (tr) | 2010-07-28 | 2019-05-21 | Gliknik Inc | Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri. |
| CN104718223A (zh) * | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| EP4299595A3 (en) | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| WO2016073917A1 (en) * | 2014-11-06 | 2016-05-12 | Gliknik Inc. | Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose |
| WO2016144608A1 (en) * | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
| DK3325011T6 (da) | 2015-07-24 | 2023-05-15 | Gliknik Inc | Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding |
| HK1255329A1 (zh) * | 2015-07-29 | 2019-08-16 | 纳米提克斯有限责任公司 | 用於清除可溶性生物分子的模块化组合物及其相关方法 |
| CN106554968A (zh) * | 2015-09-29 | 2017-04-05 | 中国农业科学院上海兽医研究所 | 日本血吸虫重组蛋白及其制备方法和应用 |
| ES2972740T3 (es) * | 2016-03-02 | 2024-06-14 | Momenta Pharmaceuticals Inc | Procedimientos relacionados con construcciones de Fc modificadas genéticamente |
| CN105647946B (zh) * | 2016-03-18 | 2019-09-20 | 江苏普瑞康生物医药科技有限公司 | 一种基于FcγRⅢa的嵌合基因及其用途 |
| JP7075100B2 (ja) * | 2016-03-30 | 2022-05-25 | エービー バイオサイエンシーズ， インコーポレイテッド | 組換え静注用免疫グロブリン（ｒＩＶＩＧ）組成物ならびにその製造及び使用方法 |
| BR112018074032A2 (pt) * | 2016-05-23 | 2019-02-26 | Momenta Pharmaceuticals, Inc. | composições e métodos relacionados a construtos de fc manipulados |
| US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
| BR112019008702A2 (pt) | 2016-11-01 | 2019-07-16 | Genmab B.V. | polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição. |
| CA3043251A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| CA3043261A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Manufacturing optimization of gl-2045, a multimerizing stradomer |
| EP3565588A4 (en) | 2017-01-06 | 2020-12-16 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS |
| MX2019009346A (es) | 2017-02-10 | 2019-10-02 | Genmab Bv | Variantes de polipeptidos y usos de los mismos. |
| CA3081353A1 (en) * | 2017-11-09 | 2019-05-16 | Medimmune, Llc | Bispecific fusion polypeptides and methods of use thereof |
| JP2021510740A (ja) | 2018-01-24 | 2021-04-30 | ゲンマブ ビー．ブイ． | ポリペプチド変種およびそれらの用途 |
| BR112020022179A2 (pt) | 2018-05-03 | 2021-02-02 | Genmab B.V. | primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit. |
| CN113101364B (zh) * | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| US12275797B2 (en) | 2018-06-22 | 2025-04-15 | Genmab Holding B.V. | Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof |
| KR20210042326A (ko) * | 2018-07-11 | 2021-04-19 | 모멘타 파머슈티컬스 인코포레이티드 | 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| KR20210043582A (ko) * | 2018-07-11 | 2021-04-21 | 모멘타 파머슈티컬스 인코포레이티드 | 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| SG11202012993SA (en) | 2018-07-13 | 2021-02-25 | Genmab As | Variants of cd38 antibody and uses thereof |
| EP3820890A1 (en) | 2018-07-13 | 2021-05-19 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| JP2023500701A (ja) | 2019-11-06 | 2023-01-10 | ジェンマブ ビー．ブイ． | 抗体変種の組み合わせおよびその使用 |
| PE20230113A1 (es) | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| EP4185388A1 (en) | 2020-07-23 | 2023-05-31 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| IL301513A (en) | 2020-10-02 | 2023-05-01 | Genmab As | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
| TW202328192A (zh) | 2021-09-06 | 2023-07-16 | 荷蘭商珍美寶公司 | 能結合ｃｄ２７之抗體、彼之變異體及彼等之用途 |
| US20250084169A1 (en) | 2022-01-12 | 2025-03-13 | Biomolecular Holdings Llc | Nk/monocyte engagers |
| IL316632A (en) | 2022-05-12 | 2024-12-01 | Genmab As | Binding agents capable of binding to CD27 in combination therapy |
| WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| TW202432177A (zh) | 2022-10-31 | 2024-08-16 | 丹麥商珍美寶股份有限公司 | Ｃｄ３８抗體及其用途 |
| KR20240156564A (ko) * | 2023-04-21 | 2024-10-30 | 상트네어바이오사이언스 주식회사 | 두 개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| AU2024271605A1 (en) | 2023-05-12 | 2025-11-13 | BioNTech SE | Antibodies capable of binding to ox40, variants thereof and uses thereof |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004781A (en) | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
| US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
| GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
| EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
| US5877396A (en) | 1993-04-23 | 1999-03-02 | Sloan Kettering Institute For Cancer Research | Mice mutant for functional Fc receptors and method of treating autoimmune diseases |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| WO1999056777A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE FcηRI RECEPTOR |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7569663B2 (en) | 2000-01-03 | 2009-08-04 | Mark L. Tykocinski | Chimeric proteins and methods for using the same |
| DE60219592T2 (de) | 2001-01-12 | 2007-12-27 | Becton Dickinson And Co. | Intrinsische fluoreszierende, selbstmultimerisierende mhc-fusionsproteine und deren komplexe |
| AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
| US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| JP2008522583A (ja) | 2002-06-14 | 2008-07-03 | セントカー・インコーポレーテツド | 修飾“ｓ”抗体 |
| DE602004022390D1 (de) | 2003-03-26 | 2009-09-17 | Apogenix Gmbh | Verbesserte fc-fusionsproteine |
| US20070041972A1 (en) | 2003-05-30 | 2007-02-22 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| WO2005089503A2 (en) | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
| JP2008506493A (ja) | 2004-07-19 | 2008-03-06 | エルテックス リミテッド | 活性物質が表面に結合している修飾された導電性表面およびその使用 |
| EP1824979A2 (en) | 2004-12-10 | 2007-08-29 | Trigen GmbH | Methods, products and uses involving platelets and/or the vasculature |
| WO2006113889A2 (en) | 2005-04-19 | 2006-10-26 | University Of Maryland | Compositions and methods for modulating interleukin-10 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| EP1991578A2 (en) | 2006-02-17 | 2008-11-19 | Rappaport Family Institute For Research in the Medical Sciences | Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases |
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| JP5732603B2 (ja) | 2007-05-11 | 2015-06-10 | アレクション ファーマ ホールディング | 骨標的アルカリホスファターゼ、キット及びその使用方法 |
| AU2008254951A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| MX394440B (es) | 2007-06-01 | 2025-03-24 | Univ Maryland | Agentes de union al receptor de la region constante fc de inmunoglobulina. |
| MX2010003099A (es) * | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| KR101808751B1 (ko) | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| WO2012001647A2 (en) | 2010-06-30 | 2012-01-05 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| TR201906652T4 (tr) | 2010-07-28 | 2019-05-21 | Gliknik Inc | Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri. |
| EP2807194A4 (en) | 2012-01-27 | 2015-12-02 | Gliknik Inc | FUSION PROTEINS WITH IGG2 HINGEOMS |
| CN104718223A (zh) * | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
-
2013
- 2013-08-20 CN CN201380053362.0A patent/CN104718223A/zh active Pending
- 2013-08-20 KR KR1020157006960A patent/KR20150058236A/ko not_active Withdrawn
- 2013-08-20 US US13/971,584 patent/US9683044B2/en active Active
- 2013-08-20 AU AU2013305885A patent/AU2013305885B2/en active Active
- 2013-08-20 RU RU2015109591A patent/RU2015109591A/ru not_active Application Discontinuation
- 2013-08-20 BR BR112015003459A patent/BR112015003459A2/pt not_active IP Right Cessation
- 2013-08-20 CA CA2882296A patent/CA2882296A1/en not_active Abandoned
- 2013-08-20 EP EP13830394.6A patent/EP2885320A4/en not_active Withdrawn
- 2013-08-20 MX MX2015002269A patent/MX2015002269A/es unknown
- 2013-08-20 HK HK15111563.7A patent/HK1210792A1/xx unknown
- 2013-08-20 WO PCT/US2013/055800 patent/WO2014031646A2/en not_active Ceased
- 2013-08-20 JP JP2015528591A patent/JP2015527366A/ja active Pending
-
2015
- 2015-02-19 IL IL237307A patent/IL237307A0/en unknown
-
2017
- 2017-05-16 US US15/596,178 patent/US20180094061A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140072582A1 (en) | 2014-03-13 |
| WO2014031646A2 (en) | 2014-02-27 |
| KR20150058236A (ko) | 2015-05-28 |
| AU2013305885A1 (en) | 2015-03-05 |
| MX2015002269A (es) | 2015-07-06 |
| EP2885320A2 (en) | 2015-06-24 |
| JP2015527366A (ja) | 2015-09-17 |
| EP2885320A4 (en) | 2016-04-06 |
| US9683044B2 (en) | 2017-06-20 |
| CA2882296A1 (en) | 2014-02-27 |
| US20180094061A1 (en) | 2018-04-05 |
| IL237307A0 (en) | 2015-04-30 |
| BR112015003459A2 (pt) | 2017-09-26 |
| HK1210792A1 (en) | 2016-05-06 |
| CN104718223A (zh) | 2015-06-17 |
| WO2014031646A3 (en) | 2014-05-01 |
| AU2013305885B2 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015109591A (ru) | Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами | |
| JP2015527366A5 (cg-RX-API-DMAC7.html) | ||
| EA201391789A1 (ru) | TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| PE20091845A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| AR095115A1 (es) | Anticuerpos que comprenden dominios constantes quiméricos | |
| CY1122216T1 (el) | Νεες ετεροδιμερικες πρωτεϊνες | |
| JP2021020910A (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| IL259927B1 (en) | Humanized antibodies against cd73 | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| EA201500204A1 (ru) | Антитела к ox40 и способы их применения | |
| RU2013141077A (ru) | Антигенсвязывающие белки | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| RU2015107693A (ru) | СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР | |
| RU2018128414A (ru) | Новое psma-связывающее антитело и его применения | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2014148704A (ru) | Конструкции одноруких моновалентных антител и их использование | |
| EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| MY153893A (en) | Antibodies against human il17 and uses thereof | |
| MX346486B (es) | Anticuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. | |
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| RU2013145243A (ru) | Гуманизированные антитела к ctla4 | |
| EA202191359A1 (ru) | Антагонистические моноклональные антитела к cd40 и их применения | |
| RU2015104625A (ru) | СПОСОБ ПОЛУЧЕНИЯ РАСТВОРИМОГО FcR В ВИДЕ Fc-ГИБРИДА С ИНЕРТНОЙ Fc-ОБЛАСТЬЮ ИММУНОГЛОБУЛИНА И ИХ ПРИМЕНЕНИЯ | |
| PE20121530A1 (es) | Inmunoglobulinas con dominio variable dual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171016 |